• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Dis . IgG response to SARS-CoV-2 and seasonal coronaviruses contributes to complement overactivation in severe COVID-19 patients

tetano

Editor, Senior Moderator
J Infect Dis


. 2022 Mar 10;jiac091.
doi: 10.1093/infdis/jiac091. Online ahead of print.
IgG response to SARS-CoV-2 and seasonal coronaviruses contributes to complement overactivation in severe COVID-19 patients


Priscila M S Castanha[SUP] 1 [/SUP], Dylan J Tuttle[SUP] 1 [/SUP], Georgios D Kitsios[SUP] 2 3 4 [/SUP], Jana L Jacobs[SUP] 5 [/SUP], Ulisses Braga-Neto[SUP] 6 [/SUP], Matthew Duespohl[SUP] 1 [/SUP], Sanjay Rathod[SUP] 7 [/SUP], Michelle M Marti[SUP] 1 [/SUP], Sarah Wheeler[SUP] 8 [/SUP], Asma Naqvi[SUP] 5 [/SUP], Brittany Staines[SUP] 5 [/SUP], John Mellors[SUP] 5 [/SUP], Alison Morris[SUP] 2 4 [/SUP], Bryan J McVerry[SUP] 2 3 4 [/SUP], Faraaz Shah[SUP] 3 [/SUP], Caitlin Schaefer[SUP] 2 [/SUP], Bernard J C Macatangay[SUP] 5 [/SUP], Barbara Methe[SUP] 2 4 [/SUP], Christian A Fernandez[SUP] 7 [/SUP], Simon M Barratt-Boyes[SUP] 1 9 [/SUP], Donald Burke[SUP] 10 [/SUP], Ernesto T A Marques[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Excessive complement activation has been implicated in the pathogenesis of COVID-19, but the mechanisms leading to this response remain unclear.
Methods: We measured plasma levels of key complement markers, SARS-CoV-2 RNA and antibodies against SARS-CoV-2 and common cold coronaviruses (CCC) in hospitalized patients with COVID-19 of moderate (n=18) and critical severity (n=37), and healthy control subjects (n=10).
Results: We confirmed that complement activation is systemically increased in COVID-19 patients and is associated with a worse disease outcome. We showed that plasma levels of C1q and circulating immune complexes (CIC) were markedly increased in severe COVID-19 patients and correlated with higher IgG titers, greater complement activation and higher disease severity score. Additional analyses showed that the classical pathway was the main arm responsible for augmented complement activation in severe patients. In addition, we demonstrated that a rapid IgG response to SARS-CoV-2 and an anamnestic IgG response to the nucleoprotein of the CCC were strongly correlated with CIC levels, complement activation, and disease severity.
Conclusions: These findings indicate that early, non-neutralizing IgG responses may play a key role in complement overactivation in severe COVID-19. Our work underscores the urgent need to develop therapeutic strategies to modify complement overactivation in COVID-19 patients.

Keywords: COVID-19; SARS-CoV-2; and antibodies; classical pathway; common cold coronaviruses; complement system.
 
Back
Top Bottom